A Phase 3 interventional study of ziltivekimab in heart attack patients

Recruiting Phase 3 NCT06118281

Study Description

A research study to evaluate the effectiveness of ziltivekimab in preventing heart disease and future cardiovascular events in patients who have had a heart attack

Study Details

Registry ID:
NCT06118281
Conditions:
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Phase:
Phase 3
Target Enrollment:
10,000 participants
Start Date:
Healthy Volunteers:
No

Study Locations (1274 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →